JP Morgan Chase (JPM) Falls 2.84% for December 21

Equities Staff |

One of the S&P 500’s big losers for Monday December 21 was JP Morgan Chase (JPM). The company’s stock fell 2.84% to $64.40 on volume of 23.82 million shares.

The stock opened the day at 65.97 and traded between a low of $64.40 and a high of $65.97. The stock finished the day down $1.88 per share. JP Morgan Chase has an average daily volume of 15.94 million and a total float of 3.68 billion shares. The 50-day SMA for JP Morgan Chase is $65.32 and its 200-day SMA is $64.34. The high for the stock over the last 52 weeks is $70.61 and the low is $50.07.

JPMorgan Chase & Co is a financial services firm and a banking institution. its segments are Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Management.

JP Morgan Chase is centered in New York, NY, and has 235,678 employees. Today’s trading day leaves the company with a market cap of $237.06 billionwith a P/E Ratio of 11. The company has a P/S ratio of 2.43, P/B ratio of 1.08, and a 2.9.

For a complete fundamental analysis analysis of JP Morgan Chase, check out’s Stock Valuation Analysis report for JPM. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…